• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

作者信息

Yang Zhao, McCaw Zachary R, Yin Guosheng

机构信息

University of Hong Kong, Hong Kong, China.

Harvard T.H. Chan School of Public Health, Boston, MA.

出版信息

N Engl J Med. 2019 May 2;380(18):e32. doi: 10.1056/NEJMc1902336.

DOI:10.1056/NEJMc1902336
PMID:31042845
Abstract
摘要

相似文献

1
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
N Engl J Med. 2019 May 2;380(18):e32. doi: 10.1056/NEJMc1902336.
2
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
N Engl J Med. 2019 May 2;380(18):e32. doi: 10.1056/NEJMc1902336.
3
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Reply.卡泊单抗治疗获得性血栓性血小板减少性紫癜。回复。
N Engl J Med. 2019 May 2;380(18):e32. doi: 10.1056/NEJMc1902336.
4
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。
J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.
5
Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?卡普雷珠单抗：在妊娠相关免疫性血栓性血小板减少性紫癜中也是改变游戏规则的药物？
Br J Haematol. 2023 Aug;202(4):725-727. doi: 10.1111/bjh.18915. Epub 2023 Jun 8.
6
Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab.卡泊单抗治疗难治性免疫性血栓性血小板减少性紫癜的图示治疗方法。
BMJ Case Rep. 2021 Aug 9;14(8):e245600. doi: 10.1136/bcr-2021-245600.
7
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura.卡泊珠单抗再治疗在免疫性血栓性血小板减少性紫癜真实单中心队列患者中的安全性和有效性
Thromb Res. 2023 Aug;228:189-190. doi: 10.1016/j.thromres.2023.06.018. Epub 2023 Jun 16.
8
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.卡普拉珠单抗作为一线治疗药物对免疫性血栓性血小板减少性紫癜治疗结局的影响。
J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22.
9
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al.用卡泊单抗治疗的免疫性血栓性血小板减少性紫癜颅内出血：埃什卡赞等人的评论
J Thromb Haemost. 2021 Oct;19(10):2644-2646. doi: 10.1111/jth.15495.
10
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜的评价。
Expert Rev Hematol. 2020 Nov;13(11):1153-1164. doi: 10.1080/17474086.2020.1819230. Epub 2020 Oct 12.